HIV patients tired of swallowing daily oral tablets may soon benefit from alternative long-lasting treatments administered once or twice per month.
Findings of a new phase 2 trial study published in The Lancet journal show that an injectable antiretroviral (ARV) therapy consisting of two drugs (cabotegravir and rilpivirine) — administered every four or eight weeks — may be as effective as a daily oral dose of the drugs in maintaining viral suppression among HIV patients.
